Merck & Co., Inc.
For the period ended Feb 3, 2026. Filed Feb 3, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Feb 3, 2026 · Filed Feb 3, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.2 · Table 3b
Table 3b
| Global | U.S. | International | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Full Year 2025 | Full Year 2024 | % Change | Full Year 2025 | Full Year 2024 | % Change | Full Year 2025 | Full Year 2024 | % Change | |
| TOTAL SALES (1) | $65,011 | $64,168 | 1 | $36,510 | $32,277 | 13 | $28,501 | $31,891 | -11 |
| PHARMACEUTICAL | 58,142 | 57,400 | 1 | 34,409 | 30,290 | 14 | 23,733 | 27,110 | -12 |
| Oncology | |||||||||
| Keytruda | 31,641 | 29,482 | 7 | 18,829 | 17,872 | 5 | 12,812 | 11,610 | 10 |
| Keytruda Qlex | 40 | - | 38 | - | 2 | - | |||
| Alliance Revenue – Lynparza (2) | 1,450 | 1,311 | 11 | 683 | 626 | 9 | 767 | 685 | 12 |
| Alliance Revenue – Lenvima (2) | 1,053 | 1,010 | 4 | 737 | 705 | 4 | 316 | 305 | 4 |
| Welireg | 716 | 509 | 41 | 603 | 466 | 29 | 113 | 43 | 161 |
| Alliance Revenue – Reblozyl (3) | 525 | 371 | 41 | 432 | 303 | 42 | 93 | 68 | 37 |
| Vaccines (4) | |||||||||
| Gardasil/Gardasil 9 | 5,233 | 8,583 | -39 | 2,641 | 2,425 | 9 | 2,592 | 6,158 | -58 |
| ProQuad/M-M-R II/Varivax | 2,451 | 2,485 | -1 | 1,885 | 1,919 | -2 | 566 | 566 | 0 |
| Vaxneuvance | 825 | 808 | 2 | 459 | 461 | 0 | 366 | 347 | 5 |
| Capvaxive | 759 | 97 | * | 730 | 96 | * | 29 | 1 | * |
| RotaTeq | 673 | 711 | -5 | 426 | 472 | -10 | 246 | 239 | 3 |
| Pneumovax 23 | 166 | 263 | -37 | 21 | 56 | -63 | 146 | 207 | -30 |
| Hospital Acute Care | |||||||||
| Bridion | 1,841 | 1,764 | 4 | 1,631 | 1,401 | 16 | 209 | 363 | -42 |
| Prevymis | 978 | 785 | 25 | 475 | 371 | 28 | 503 | 414 | 21 |
| Zerbaxa | 312 | 252 | 24 | 186 | 146 | 28 | 126 | 106 | 18 |
| Dificid | 247 | 340 | -27 | 202 | 303 | -33 | 45 | 37 | 20 |
| Cardiometabolic & Respiratory | |||||||||
| Winrevair | 1,443 | 419 | * | 1,358 | 408 | * | 85 | 11 | * |
| Alliance Revenue - Adempas/Verquvo (5) | 470 | 415 | 13 | 421 | 388 | 8 | 49 | 27 | 81 |
| Adempas (6) | 312 | 287 | 9 | 312 | 287 | 9 | |||
| Ohtuvayre | 178 | - | 178 | - | |||||
| Virology | |||||||||
| Lagevrio | 380 | 964 | -61 | 101 | 176 | -43 | 278 | 787 | -65 |
| Isentress/Isentress HD | 325 | 394 | -18 | 181 | 185 | -3 | 144 | 209 | -31 |
| Delstrigo | 306 | 249 | 23 | 56 | 56 | 1 | 250 | 193 | 29 |
| Pifeltro | 171 | 163 | 5 | 111 | 113 | -1 | 59 | 50 | 18 |
| Neuroscience | |||||||||
| Belsomra | 186 | 222 | -16 | 82 | 72 | 13 | 104 | 150 | -31 |
| Immunology | |||||||||
| Simponi | 543 | -100 | 543 | -100 | |||||
| Remicade | 114 | -100 | 114 | -100 | |||||
| Diabetes (7) | |||||||||
| Januvia | 1,604 | 1,334 | 20 | 999 | 469 | 113 | 605 | 865 | -30 |
| Janumet | 940 | 935 | 1 | 268 | 161 | 66 | 672 | 774 | -13 |
| Other Pharmaceutical (8) | 2,917 | 2,590 | 13 | 676 | 640 | 6 | 2,244 | 1,951 | 15 |
| ANIMAL HEALTH | 6,354 | 5,877 | 8 | 1,953 | 1,861 | 5 | 4,401 | 4,016 | 10 |
| Livestock | 3,896 | 3,462 | 13 | 807 | 732 | 10 | 3,089 | 2,729 | 13 |
| Companion Animal | 2,458 | 2,415 | 2 | 1,146 | 1,129 | 2 | 1,312 | 1,287 | 2 |
| Other Revenues (9) | 515 | 891 | -42 | 148 | 126 | 17 | 367 | 765 | -52 |
*200% or greater
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $10,711 million and $13,448 million on a global basis for December YTD 2025 and 2024, respectively.
(5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in the Company's marketing territories.
(7) Total Diabetes sales were $2,862 million and $2,599 million on a global basis for December YTD 2025 and 2024, respectively.
(8) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $436 million and $170 million on a global basis for December YTD 2025 and 2024, respectively.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $138 million and $106 million on a global basis for December YTD 2025 and 2024, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.